MentionFox
Home › funding signals › ImmunoGenesis, Inc.
Form D · on the record

ImmunoGenesis — $5.75M Form D filing, January 2025

Before you sell to, join or invest in ImmunoGenesis, Inc.

MentionFox check on ImmunoGenesis, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/immunogenesis-inc-form-d-25000001

Check ImmunoGenesis, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about ImmunoGenesis, Inc.?

ImmunoGenesis, Inc. filed a Form D with the Securities and Exchange Commission on 2025-01-15.

ImmunoGenesis, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 15, 2025. The filing reports $5.75M sold. Its industry group is Biotechnology. It names Jennifer Barlow (Executive Officer, Director), Ted Koutouzis (Director), Robert Stein (Director) (SEC Form D, January 15, 2025).

125 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Andersen Aggregator LLC$1.9BBusiness services
AT Umbrella LLC$1.9BBusiness services
Legora, Inc.$221MAI and software
MD INVESTMENT LLC$169MBusiness services
Serval Inc.$149MAI and software
Check one company free

2 more Biotechnology raises in Pennsylvania within 90 days ↓

Is this your company?

Key facts

Run the free check on ImmunoGenesis, Inc. →

Sell to companies like ImmunoGenesis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

ImmunoGenesis, Inc.

New Form D on file · 2025-01-15 · the record

$5.75M
raise on the record
D
filing
2
investors in
PENNSYLVANIA
based
Open the record →

What the record says

FilingForm D
Filed2025-01-15
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedDoylestown, PENNSYLVANIA
CIK2018057
Accession0002018057-25-000001

Pitching, partnering or investing alongside them? See who really runs and owns ImmunoGenesis, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind ImmunoGenesis, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.

What do you want to do with ImmunoGenesis, Inc.?

Get the full cited report on ImmunoGenesis, Inc.

What the filing shows about ImmunoGenesis, Inc.

  • 2 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on ImmunoGenesis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives ImmunoGenesis, Inc.'s address as 263 North Main St., Apt 417, Doylestown, PA 18901.

What the filing says

  • Offered: $24,999,999. Sold: $5,749,998. Left to sell: $19,250,001. (filing)
  • Investors: 2 had already invested. (filing)
  • Date of first sale: December 18, 2024. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on ImmunoGenesis, Inc. See pricing

Is ImmunoGenesis, Inc. a real, registered company?

ImmunoGenesis, Inc. is a registered filer with the SEC (CIK 2018057) and has filed since 2024-04-03. 2 filings are on record, the latest on 2025-01-15.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs ImmunoGenesis, Inc.?

ImmunoGenesis, Inc.'s Form D of 2025-01-15 names Jennifer Barlow, Ted Koutouzis, Robert Stein and 3 more as its officers, directors or promoters.

How much has ImmunoGenesis, Inc. raised?

Its new offerings report $50.18M sold across 2 offerings, as its own filings state.

Filing history · 2 filings on this registrant
Form D · 2024-04-03 · $44.43MForm D · 2025-01-15 · $5.75M · this page 2024-04-03 2025-01-15

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week

Trailing twelve months. 763 filings in Biotechnology, totalled by week.

Want the whole picture on ImmunoGenesis, Inc.?

What the filing shows about ImmunoGenesis, Inc.

  • 2 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on ImmunoGenesis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on ImmunoGenesis, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind ImmunoGenesis, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for ImmunoGenesis, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

ImmunoGenesis, Inc.: Raised $5.75M, Form D filed 2025-01-15
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/immunogenesis-inc-form-d-25000001
Last updated 2026-11-06
Primary record: SEC filing 1 · SEC filing 2
ImmunoGenesis raised $5.75M — SEC Form D filing, January 2025. MentionFox, 2026-11-06. https://mentionfox.com/funding/immunogenesis-inc-form-d-25000001